ECA combines ephedrine, caffeine, and aspirin to raise energy use and curb appetite, producing modest, reliable short-term fat loss with some muscle sparing. The benefit is small and proven only over weeks to months. It consistently raises heart rate and blood pressure and, rarely, has caused serious heart and brain events. (Full Review)

Protocol

Standard Dose

~20–25 mg ephedrine + 200 mg caffeine

Often with ~80–325 mg aspirin per dose in the full ECA form

Frequency & Timing

2–3× daily, split dosing

Morning and early afternoon; last dose well before evening

Aspirin Component

Optional (EC vs full ECA)

Incremental benefit in humans unproven; many use ephedrine-caffeine only

Time to effect

Weight & Fat Loss

Weeks to months

Most trial benefits documented over 8 weeks to 6 months

Thermogenesis

Within first hours

Thermogenic effect felt acutely within the first hours of dosing

Appetite Suppression

Within first hours

Appetite effects felt acutely within the first hours of dosing

Benefits

High: Short-term weight and fat loss; increased thermogenesis and energy expenditure

Medium: Preservation of lean body mass during caloric restriction; favorable short-term lipid changes

Low: Appetite suppression

Speculative: Acute endurance and power performance

Contraindications

MAOIs (phenelzine, tranylcypromine, selegiline)

Cardiovascular disease

Uncontrolled hypertension (>~140/90 mmHg)

Arrhythmias

Recent myocardial infarction (<90 days) or stroke

Hyperthyroidism

Pheochromocytoma

Narrow-angle glaucoma

Benign prostatic hyperplasia with urinary retention

Seizure disorders

Severe anxiety disorders

Pregnancy or breastfeeding

Under 18

Key Interactions

Other sympathomimetics and decongestants (pseudoephedrine, phenylephrine, other stimulants)

Stimulant medications (amphetamines, methylphenidate)

Beta-blockers (propranolol, metoprolol)

Other antihypertensives (ACE inhibitors, ARBs, calcium channel blockers)

Cardiac glycosides (digoxin) and heart-sensitizing drugs (halothane anesthesia)

Anticoagulants and antiplatelet agents (warfarin, clopidogrel)

Other NSAIDs (ibuprofen, naproxen) and gastric irritants

Caffeine-containing supplements and beverages

Additive stimulant or blood-pressure supplements (synephrine/bitter orange, yohimbine, high-dose green tea extract)

Risk & Side Effects

High: Cardiovascular stimulation; neuropsychiatric and central nervous system effects

Medium: Serious cardiovascular and cerebrovascular events; gastrointestinal disturbances

Low: Dependence, tolerance, and withdrawal

Speculative: Long-term cardiometabolic and longevity harm

Monitoring

Marker	Target	Why
Resting Blood Pressure	<120/80 mmHg	Detects adrenergic blood-pressure elevation; the primary safety signal
Resting Heart Rate	50–70 bpm	Tracks sympathetic stimulation and tachycardia risk
Fasting Glucose	75–90 mg/dL	Stimulants can raise blood glucose; tracks metabolic effect
Lipid Panel (LDL, HDL, Triglycerides)	LDL <100, HDL >50, TG <80 mg/dL	Tracks the favorable/unfavorable lipid shifts reported in trials
TSH	0.5–2.5 mIU/L	Excludes hyperthyroidism, which dangerously amplifies adrenergic effects
Electrocardiogram (ECG)	Normal sinus rhythm	Screens for arrhythmia before and during use

Cadence: Blood pressure and heart rate several times weekly for the first 2–4 weeks, then every 1–2 weeks while in use; clinical review and lab reassessment roughly every 1–3 months if use continues.

Qualitative Assessment

Sleep quality and duration
Anxiety, jitteriness, or irritability levels
Palpitations or chest discomfort
Energy levels and appetite
Subjective recovery and mood

ECA for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment